checkAd

    DGAP-News  516  0 Kommentare MOLOGEN AG: First combination trial with MGN1703 and a checkpoint inhibitor in collaboration with MD Anderson - Seite 3


    industry e.V. (VCI)

    MIDGE(R), dSLIM(R), EnanDIM(R) and MOLOGEN(R) are registered trademarks of
    MOLOGEN AG.

    Contact
    Claudia Nickolaus
    Head of Investor Relations & Corporate Communications
    Tel: +49 - 30 - 84 17 88 - 38
    Fax: +49 - 30 - 84 17 88 - 50
    investor@mologen.com

    Note about risk for future predictions
    Certain information in this report contains forward-looking statements or
    the corresponding statements with negation or versions deviating from this
    or comparable terminology. These are described as forward-looking
    statements. In addition, all of the information given here that refers to
    planned or future results of business areas, key financial figures,
    developments of the financial situation or other financial figures or
    statistical data, is to be understood as such forward-looking statements.
    The company points out to investors that they should not rely on these
    forward-looking statements as predictions about actual future events. The
    company is not obligated and refuses to accept any liability for the
    forward-looking statements and has no obligation to update such statements
    in order to accurately reflect the current situation.


    ---------------------------------------------------------------------------

    19.01.2016 Dissemination of a Corporate News, transmitted by DGAP - a
    service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.

    The DGAP Distribution Services include Regulatory Announcements,
    Financial/Corporate News and Press Releases.
    Media archive at www.dgap-medientreff.de and www.dgap.de

    ---------------------------------------------------------------------------


    Language: English
    Company: MOLOGEN AG
    Fabeckstraße 30
    14195 Berlin
    Germany
    Phone: 030 / 841788-0
    Fax: 030 / 841788-50
    E-mail: presse@mologen.com
    Internet: www.mologen.com
    ISIN: DE0006637200
    WKN: 663720
    Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
    Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
    Stuttgart


    End of News DGAP News Service
    ---------------------------------------------------------------------------

    430523 19.01.2016
    Seite 3 von 3



    Diskutieren Sie über die enthaltenen Werte



    EQS Group AG
    0 Follower
    Autor folgen

    Weitere Artikel des Autors


    Verfasst von EQS Group AG
    DGAP-News MOLOGEN AG: First combination trial with MGN1703 and a checkpoint inhibitor in collaboration with MD Anderson - Seite 3 DGAP-News: MOLOGEN AG / Key word(s): Alliance/Study MOLOGEN AG: First combination trial with MGN1703 and a checkpoint inhibitor in collaboration with MD Anderson 19.01.2016 / 08:09 The issuer is solely responsible for the content of this …